Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes

References

• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• BrandtJDVanDenburghAMChenKWhitcupSMComparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trialOphthalmology200110861023103111382623
   PubMed Web of Science ®Google Scholar
• EinarsonTRKulinNATingeyDIskedjianMMeta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucomaClin Ther200022121502151511192141
   PubMed Web of Science ®Google Scholar
• FungATReidSEJonesMPHealeyPRMcCluskeyPJCraigJCMeta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucomaBr J Ophthalmol2007911626816956912
   PubMed Web of Science ®Google Scholar
• NoeckerRSDirksMSChoplinNTBernsteinPBatoosinghALWhitcupSMA six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucomaAm J Ophthalmol20031351556312504698
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCASchoutenJSZeegersMPHendrikseFPrinsMHIntraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trialsOphthalmology200511271177118515921747
   PubMed Web of Science ®Google Scholar
• StjernschantzJSelénGSjöquistBResulBPreclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogueAdv Prostaglandin Thromboxane Leukot Res1995235135187732899
   PubMedGoogle Scholar
• WhitsonJTTravoprost – a new prostaglandin analogue for the treatment of glaucomaExpert Opin Pharmacother20023796597712083996
   PubMedGoogle Scholar
• WoodwardDFKraussAHChenJReplacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compoundsBr J Pharmacol200013081933194310952685
   PubMed Web of Science ®Google Scholar
• AnthonyTLPierceKLStamerWDReganJWProstaglandin F2 alpha receptors in the human trabecular meshworkInvest Ophthalmol Vis Sci19983923153219477988
   PubMed Web of Science ®Google Scholar
• HellbergMRKeTLHaggardKKlimkoPGDeanTRGraffGThe hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissueJ Ocul Pharmacol Ther20031929710312804054
   PubMed Web of Science ®Google Scholar
• MatsuoTCynaderMSLocalisation of prostaglandin F2 alpha and E2 binding sites in the human eyeBr J Ophthalmol19927642102131327095
   PubMed Web of Science ®Google Scholar
• MukhopadhyayPBianLYinHBhattacherjeePPatersonCLocalization of EP(1) and FP receptors in human ocular tissues by in situ hybridizationInvest Ophthalmol Vis Sci200142242442811157877
   PubMed Web of Science ®Google Scholar
• CantorLBHoopJWudunnDLevels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataractBr J Ophthalmol200791562963217135335
   PubMed Web of Science ®Google Scholar
• SharifNAWilliamsGWKellyCRBimatoprost and its free acid are prostaglandin FP receptor agonistsEur J Pharmacol20014322–321121311740958
   PubMed Web of Science ®Google Scholar
• SimmonsSTDirksMSNoeckerRJBimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trialsAdv Ther200421424726215605619
   PubMed Web of Science ®Google Scholar
• WoodwardDFKraussAHChenJThe pharmacology of bimatoprost (Lumigan)Surv Ophthalmol200145Suppl 4S337S34511434936
   PubMed Web of Science ®Google Scholar
• DayDGSharpeEDAtkinsonMJStewartJAStewartWCThe clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patientsEye (Lond)200620558359015933751
   PubMed Web of Science ®Google Scholar
• KonstasAGKatsimbrisJMLallosNBoukarasGPJenkinsJNStewartWCLatanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patientsOphthalmology2005112226226615691561
   PubMed Web of Science ®Google Scholar
• KatzLJCohenJSBatoosinghALFelixCShuVSchiffimanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol2010149466167120346780
   PubMed Web of Science ®Google Scholar
• NakamuraTTeshimaMKitaharaTSensitive and real-time method for evaluating corneal barrier considering tear flowBiol Pharm Bull201033110711020045945
   PubMed Web of Science ®Google Scholar
• LiangHPaulyARianchoLBaudouinCBrignole-BaudouinFToxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium systemBr J Ophthalmol201195686987521429894
   PubMed Web of Science ®Google Scholar
• AbelsonMBHellerWShapiroAMSiEHsuPBowmanLMClinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trialAm J Ophthalmol2008145695996518374301
   PubMed Web of Science ®Google Scholar
• DeLeonJSilversteinBEAllaireCBesifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and childrenClin Drug Investig2012325303317
   Web of Science ®Google Scholar
• SilversteinBEAllaireCBatemanKMGearingerLSMorrisTWComstockTLEfficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childrenClin Ther2011331132621397770
   PubMed Web of Science ®Google Scholar
• Schlotzer-SchrehardtUZenkelMNusingRMExpression and localization of FP and EP prostanoid receptor subtypes in human ocular tissuesInvest Ophthalmol Vis Sci20024351475148711980863
   PubMed Web of Science ®Google Scholar
• OcklindAEffect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sectionsExp Eye Res19986721791919733584
   PubMed Web of Science ®Google Scholar
• LindseyJDKashiwagiKBoyleDKashiwagiFFiresteinGSWeinrebRNProstaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cellsCurr Eye Res19961588698758921230
   PubMed Web of Science ®Google Scholar
• OoiYHOhDJRheeDJEffect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cellsInvest Ophthalmol Vis Sci200950115259526519443729
   PubMed Web of Science ®Google Scholar
• WeinrebRNLindseyJDMetalloproteinase gene transcription in human ciliary muscle cells with latanoprostInvest Ophthalmol Vis Sci200243371672211867589
   PubMed Web of Science ®Google Scholar
• WeinrebRNKashiwagiKKashiwagiFTsukaharaSLindseyJDProstaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cellsInvest Ophthalmol Vis Sci19973813277227809418730
   PubMed Web of Science ®Google Scholar
• StjernschantzJSelénGOcklindAResulBEffects of latanoprost and related prostaglandin analoguesAlmAWeinrebRNUveoscleral Outflow: Biology and Clinical AspectsLondonMosby19985772
   Google Scholar
• IchhpujaniPKatzLJHolloGComparison of human ocular distribution of bimatoprost and latanoprostJ Ocul Pharmacol Ther201228213414522136089
   PubMed Web of Science ®Google Scholar
• KraussAHWoodwardDFUpdate on the mechanism of action of bimatoprost: a review and discussion of new evidenceSurv Ophthalmol200449Suppl 1S5S1115016556
   PubMed Web of Science ®Google Scholar
• DaviesSSJuWKNeufeldAHAbranDChemtobSRobertsLJHydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitroJ Ocul Pharmacol Ther2003191455412648303
   PubMed Web of Science ®Google Scholar
• FaulknerRSharifNAOrrSAqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of Lumigan or TravatanJ Ocul Pharmacol Ther201026214715620307216
   PubMed Web of Science ®Google Scholar
• SharifNAKaddour-DjebbarIAbdel-LatifAACat iris sphincter smooth-muscle contraction: comparison of FP-class prostaglandin analog agonist activitiesJ Ocul Pharmacol Ther200824215216318355130
   PubMed Web of Science ®Google Scholar
• StamerWDPiwnicaDJolasTCellular basis for bimatoprost effects on human conventional outflowInvest Ophthalmol Vis Sci201051105176518120435598
   PubMed Web of Science ®Google Scholar
• AptelFCucheratMDenisPEfficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trialsJ Glaucoma200817866767319092464
   PubMed Web of Science ®Google Scholar
• CravenERLiuCCBatoosinghASchiffmanRMWhitcupSMA randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostClin Ophthalmol201041433144021188155
   PubMedGoogle Scholar
• MajumdarSHippalgaonkarKRepkaMAEffect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit corneaInt J Pharm20083481–217517817897799
   PubMed Web of Science ®Google Scholar
• OgundeleABJasekMCAqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbitsClin Ophthalmol201041447145021188157
   PubMedGoogle Scholar
• PellinenPHuhtalaATolonenALokkilaJMaenpaaJUusitaloHThe cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivoCurr Eye Res201237214515422049909
   PubMed Web of Science ®Google Scholar
• XiaoXHeHLinZTherapeutic effects of epidermal growth factor on benzalkonium chloride-induced dry eye in a mouse modelInvest Ophthalmol Vis Sci201253119119722159022
   PubMed Web of Science ®Google Scholar
• XiongCChenDLiuJA rabbit dry eye model induced by topical medication of a preservative benzalkonium chlorideInvest Ophthalmol Vis Sci20084951850185618436819
   PubMed Web of Science ®Google Scholar
• StevensAMKestelynPADeBDKestelynPGBenzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by fare meter: a randomized clinical trialActa Ophthalmol2012903e221e22422489894
   PubMed Web of Science ®Google Scholar